Cardiovascular Outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial

American Journal of Kidney Diseases

Volumn 48, Issue 5, 2006, Pages 739-751

  Norris, Keith ^a   Bourgoigne, Jacque ^a   Gassman, Jennifer ^a   Hebert, Lee ^a   Middleton, John ^a   Phillips, Robert A ^a   Randall, Otelio ^a   Rostand, Stephen ^a   Sherer, Susan ^a   Toto, Robert D ^a   Wright Jr , Jackson T ^a   Wang, Xuelei ^a   Greene, Tom ^a   Appel, Lawrence J ^a   Lewis, Julia ^a  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

blocker; calcium channel blocker; cardiovascular; chronic kidney disease; hypertension; Inhibitor

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; POTASSIUM; PROTEIN; RAMIPRIL; SODIUM;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE URINE LEVEL; DISEASE DURATION; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART FAILURE; HEART INFARCTION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROSCLEROSIS; POTASSIUM URINE LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SODIUM URINE LEVEL; STROKE; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AFRICAN AMERICANS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CREATININE; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHROSCLEROSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS;

EID: 33751014040     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.08.004     Document Type: Article

References (42)

1. Shulman N.B., Ford C.E., Hall W.D., et al., The Hypertension Detection and Follow-Up Program Cooperative Group. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the Hypertension Detection and Follow-Up Program. Hypertension 13 (1989) I80-I93
2. Mann J.F., Gerstein H.C., Pogue J., Bosch J., and Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134 (2001) 629-636
3. Foley R.N., Murray A.M., Li S., et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 16 (2005) 489-495
4. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
5. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
6. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003) 1050-1065
7. Brown W.W., Peters R.M., Ohmit S.E., et al. Early detection of kidney disease in community settings: The Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 42 (2003) 22-35
8. Curb J.D., Pressel S.L., Cutler J.A., et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. [erratum in JAMA 277:1356, 1997]. JAMA 276 (1996) 1886-1892
9. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
10. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). [erratum in JAMA 289:178, 2003]. JAMA 288 (2002) 2981-2997
11. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997) 1857-1863
12. Agodoa L.Y., Appel L., Bakris G.L., et al., African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285 (2001) 2719-2728
13. Wright Jr. J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288 (2002) 2421-2431
14. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
15. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
16. Berl T., Hunsicker L.G., Lewis J.B., et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138 (2003) 542-549
17. Ruilope L.M., Salvetti A., Jamerson K., et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J Am Soc Nephrol 12 (2001) 218-225
18. Anderson P.K., and Gill R.D. Cox's regression model for counting processes: A large sample study. Ann Stat 10 (1982) 1100-1120
19. Hunsicker L.G., Adler S., Caggiula A., et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51 (1997) 1908-1919
20. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial [erratum in Lancet 361:1230, 2003]. Lancet 361 (2003) 117-124
21. Exner D.V., Dries D.L., Domanski M.J., and Cohn J.N. Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
22. Julius S., Kjeldsen S.E., Weber M., et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363 (2004) 2022-2031
23. Wright Jr. J.T., Dunn J.K., Cutler J.A., et al., ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 293 (2005) 1595-1608
24. Xie J.X., Sasaki S., Joossens J.V., and Kesteloot H. The relationship between urinary cations obtained from the INTERSALT Study and cerebrovascular mortality. J Hum Hypertens 6 (1992) 17-21
25. He J., and Whelton P.K. What is the role of dietary sodium and potassium in hypertension and target organ injury?. Am J Med Sci 317 (1999) 152-159
26. Romundstad S., Holmen J., Kvenild K., Hallan H., and Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: A 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 42 (2003) 466-473
27. Gall M.A., Borch-Johnsen K., Hougaard P., Nielsen F.S., and Parving H.H. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 44 (1995) 1303-1309
28. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., and Holman R.R. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63 (2003) 225-232
29. Lea J., Greene T., Hebert L., et al., AASK Study Investigators. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med 165 (2005) 947-953
30. Rostand S.G. US minority groups and end-stage renal disease: A disproportionate share. Am J Kidney Dis 19 (1992) 411-413 (comment)
31. Powe N.R. To have and have not: Health and health care disparities in chronic kidney disease. Kidney Int 64 (2003) 763-772
32. Tarver-Carr M.E., Powe N.R., Eberhardt M.S., et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors. J Am Soc Nephrol 13 (2002) 2363-2370
33. Qureshi A.I., Suri M.F., Saad M., and Hopkins L.N. Educational attainment and risk of stroke and myocardial infarction. Med Sci Monit 9 (2003) CR466-CR473
34. American Heart Association. Heart Disease and Stroke Statistics-2005 Update (2005), American Heart Association, Dallas, TX
35. Ganguli M.C., Grimm Jr. R.H., Svendsen K.H., Flack J.M., Grandits G.A., and Elmer P.J. Higher education and income are related to a better Na:K ratio in blacks: Baseline results of the Treatment of Mild Hypertension Study (TOMHS) data. Am J Hypertens 10 (1997) 979-984
36. Mittleman M.A., Maclure M., Nachnani M., Sherwood J.B., and Muller J.E. Educational attainment, anger, and the risk of triggering myocardial infarction onset. The Determinants of Myocardial Infarction Onset Study Investigators. Arch Intern Med 157 (1997) 769-775
37. Merritt M.M., Bennett G.G., Williams R.B., Sollers III J.J., and Thayer J.F. Low educational attainment, John Henryism, and cardiovascular reactivity to and recovery from personally relevant stress. Psychosom Med 66 (2004) 49-55
38. Troxel W.M., Matthews K.A., Bromberger J.T., and Sutton-Tyrrell K. Chronic stress burden, discrimination, and subclinical carotid artery disease in African American and Caucasian women. Health Psychol 22 (2003) 300-309
39. Klassen P.S., Lowrie E.G., Reddan D.N., et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287 (2002) 1548-1555
40. Kalantar-Zadeh K., Block G., Humphreys M.H., and Kopple J.D. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 63 (2003) 793-808
41. Tokmakova M.P., Skali H., Kenchaiah S., et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: The Survival and Ventricular Enlargement (SAVE) Study. Circulation 110 (2004) 3667-3673
42. Smith G.L., Shlipak M.G., Havranek E.P., et al. Race and renal impairment in heart failure: Mortality in blacks versus whites. Circulation 111 (2005) 1270-1277